ClinicalTrials.gg
CompletedNCT03407599Updated Jun 19, 2019

A Trial Comparing the Pharmacokinetic Properties of Fast-acting Insulin Aspart Between Children, Adolescents and Adults With Type 1 Diabetes

A Phase 1 interventional study of Faster aspart and Insulin aspart (NovoRapid®) in Diabetes and Diabetes Mellitus, Type 1, sponsored by Novo Nordisk A/S. Completed at 1 site in Germany. Open to participants aged 6 Years to 64 Years. Per ClinicalTrials.gov, last updated 2019-06-19.

Primary conditionDiabetes Mellitus, Type 1Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 1
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 1, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2018, 8 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
6 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 87 studies testing Insulin Aspart in Diabetes Mellitus, Type 1 — 2 open to participants now, 2 under way, none of them phase 3. Insulin Aspart · Diabetes Mellitus, Type 1.

Enrollment
46th of 87
46 · median 50
Started
2018
with 4 others
Phase 1
27 of 87
none open now
Registered
69th of 87
by date
Lead sponsor
55 of 87
Novo Nordisk A/S

Among the 87 studies testing Insulin Aspart in Diabetes Mellitus, Type 1, this one is the 46th largest by enrollment, is one of 5 that started in 2018, is one of 27 in phase 1, and was the 69th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

2 of the 87 studies testing Insulin Aspart in Diabetes Mellitus, Type 1 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Insulin Aspart

Insulin Aspart: first FDA approval 2000 (NOVOLOG PENFILL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 412 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 258 (63%) stop at 75 or younger; 185 take children under 18; 64 take healthy volunteers.

This study: 6 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies testing Insulin Aspart in Diabetes Mellitus, Type 1, or all of them as a file.
02

Study summary

The study is done to compare how faster aspart is taken up, broken down and removed from the body between different age groups (children [6-11 years], adolescents [12-17 years] and adults [18-64 years]) who have diabetes. The blood sugar (glucose) lowering effect of faster aspart will also be investigated after consuming a meal replacement drink. The effects of faster aspart will be compared to the effects of NovoRapid®.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 1

Browse trials for

04

In context

Diabetes Mellitus, Type 1 Reclassified

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

This study's enrollment of 46 is above the median of 40 across 2,820 interventional studies indexed under Diabetes Mellitus, Type 1.

Browse Diabetes Mellitus, Type 1 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 1, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
6 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged 6-64 years (both inclusive) at the time of signing
  • Diagnosed with type 1 diabetes greater than or equal to 12 months prior to the day of screening
  • for children and adolescents (male and female) between the 3rd and 97th BMI percentile and for adults less than or equal to 28.0 kg/sqm

Exclusion criteria

Exclusion Criteria:

  • Subject who has donated any blood or plasma in the past month or more than 500 mL within 3 months prior to screening
  • Smoker (defined as a subject who is smoking at least one cigarette, cigar or pipe daily)
  • Not able or willing to refrain from smoking and use of nicotine substitute products during the inpatient period
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    Faster aspart followed by insulin aspart (NovoRapid®)

    Participants will receive single dose of fast-acting insulin aspart followed by single dose of NovoRapid® on two separate dosing visits. The dosing visits will be separated by a wash-out period of 3-22 days.

    Drug: Faster aspart · Drug: Insulin aspart (NovoRapid®)

  • Experimental
    Insulin aspart (NovoRapid®) followed by faster aspart

    Participants will receive single dose of NovoRapid® followed by single dose of fast-acting insulin aspart on two separate dosing visits. The dosing visits will be separated by a wash-out period of 3-22 days.

    Drug: Faster aspart · Drug: Insulin aspart (NovoRapid®)

Interventions

  • DrugFaster aspart

    An injection of fast-acting insulin aspart 0.2 U/kg body weight under the skin just prior to a standard meal.

  • An injection of insulin aspart (NovoRapid®) 0.2 U/kg body weight under the skin just prior to a standard meal.

07

What researchers measure

Primary outcomes

  1. AUC(IAsp),0-12h, area under the serum insulin aspart concentration-time curve from 0 to 12 hours

    Calculated based on insulin aspart measured in blood.

    Time frame: 0-12 hours

Secondary outcomes

  1. AUCIAsp,0-15min, area under the serum insulin aspart concentration-time curve 0 to 15 minutes

    Calculated based on insulin aspart measured in blood.

    Time frame: 0-15 minutes

  2. AUCIAsp,0-30min, area under the serum insulin aspart concentration-time curve from 0 to 30 minutes

    Calculated based on insulin aspart measured in blood.

    Time frame: 0-30 minutes

  3. AUCIAsp,0-1hr, area under the serum insulin aspart concentration-time curve from 0 to 1 hour

    Calculated based on insulin aspart measured in blood.

    Time frame: 0-1 hour

  4. AUCIAsp,0-1½hr, area under the serum insulin aspart concentration-time curve from 0 to 1½ hour

    Calculated based on insulin aspart measured in blood.

    Time frame: 0-1½ hour

  5. AUCIAsp,0-2hr, area under the serum insulin aspart concentration-time curve from 0 to 2 hours

    Calculated based on insulin aspart measured in blood.

    Time frame: 0-2 hours

  6. Cmax,IAsp, maximum observed serum insulin aspart concentration

    Calculated based on insulin aspart measured in blood.

    Time frame: 0-12 hours

  7. tmax,IAsp, time to maximum observed serum insulin aspart concentration

    Calculated based on insulin aspart measured in blood.

    Time frame: 0-12 hours

  8. Onset of appearanceIAsp, time from trial product administration until the first time serum insulinaspart concentration greater than or equal to Lower Limit Of Quantitation (LLOQ)

    Calculated based on insulin aspart measured in blood.

    Time frame: 0-12 hours

  9. Duration of exposureIAsp, time from trial product administration until the first time serum insulin aspart concentration is equal to LLOQ in the terminal part of the curve

    Calculated based on insulin aspart measured in blood.

    Time frame: 0-12 hours

  10. Time to 50% Cmax, IAsp, the first time point where the insulin aspart concentration equals 50% of Cmax,IAsp

    Calculated based on insulin aspart measured in blood.

    Time frame: 0-12 hours

  11. Time to late 50% Cmax,IAsp, the last time point where the insulin aspart concentration equals 50% of Cmax,IAsp

    Calculated based on insulin aspart measured in blood.

    Time frame: 0-12 hours

  12. Mean change in plasma glucose concentration from 0-1 hour after administration

    Calculated based on glucose concentration measured in plasma.

    Time frame: 0-1 hour

  13. Mean change in plasma glucose concentration from 0-2 hours after administration

    Calculated based on glucose concentration measured in plasma.

    Time frame: 0-2 hours

  14. Mean change in plasma glucose concentration from 0-6 hours after administration

    Calculated based on glucose concentration measured in plasma.

    Time frame: 0-6 hours

  15. Change from baseline in plasma glucose concentration 1 hour after administration

    Calculated based on glucose concentration measured in plasma.

    Time frame: Pre-dose (0 hour), 1 hour

  16. Change from baseline in plasma glucose concentration 2 hours after administration

    Calculated based on glucose concentration measured in plasma.

    Time frame: Pre-dose (0 hour), 2 hours

  17. Plasma glucose concentration 1 hour after administration

    Calculated based on glucose concentration measured in plasma.

    Time frame: 1 hour after administration

  18. Plasma glucose concentration 2 hours after administration

    Calculated based on glucose concentration measured in plasma.

    Time frame: 2 hours after administration

  19. Maximum plasma glucose excursion after administration

    Calculated based on glucose concentration measured in plasma.

    Time frame: 0-6 hours

  20. Maximum plasma glucose concentration after administration

    Calculated based on glucose concentration measured in plasma.

    Time frame: 0-6 hours

  21. Time to maximum plasma glucose concentration after administration

    Calculated based on glucose concentration measured in plasma.

    Time frame: 0-6 hours

  22. Minimum plasma glucose concentration after administration

    Calculated based on glucose concentration measured in plasma.

    Time frame: 0-6 hours

  23. Number of adverse events

    Count of events

    Time frame: From screening day 1 up to the study completion day 68

  24. Number of hypoglycaemic episodes

    Count of hypoglycaemic episodes

    Time frame: From screening day 1 up to the study completion day 68

08

Study locations

1 site
  • Novo Nordisk Investigational Site
    Hannover, 30173, Germany
09

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Jul 2018, 5 months.

Of 98 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 13. This study's 5 months is below that.

Counting every sponsor, half of 153 studies reached it within 12 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2018
First posted
Jan 23, 2018
StartActual
Jan 8, 2018
Primary completionActual
Jul 5, 2018
CompletionActual
Jul 5, 2018
Last update
Jun 19, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 19, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03407599
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jan 23, 2018
Start date
Jan 8, 2018
Primary completion
Jul 5, 2018
Completion
Jul 5, 2018
Last update
Jun 19, 2019

Study contacts

Clinical Reporting Anchor and Disclosure (1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin Aspart

Start the discussion